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ABSTRACT Epstein-Barr virus (EBV) DNA structure
and gene expression were analyzed in tissue specimens from
oral hairy leukoplakia (HLP), a mucocutaneous lesion that
develops in patients infected with human immunodeficiency
virus (HIV). The structure of the terminal restriction enzyme
fragments of EBV revealed that HLP is a permissive infection
without a predominant, detectable population ofEBV episomal
DNA. In RNA preparations from this uniquely permissive
infection, EBV replicative mRNAs could be identified by
Northern analysis; however, the virally encoded small nuclear
RNAs, the EBERs, were not detected in most HLP RNA
preparations. In situ hybridization detected EBER expression
in very rare cells. These data indicate that unlike other viral
small nuclear RNAs, the EBERs are not expressed during viral
replication and must participate in the complex maintenance of
latent EBV infection.
Oral hairy leukoplakia (HLP) is a newly recognized lesion,
most often located on the tongue, that occurs almost exclu-
sively in patients with human immunodeficiency virus (HIV)
infection (1). Epstein-Barr virus (EBV), usually thought of as
a lymphotrophic herpesvirus, is the etiologic agent of this
mucocutaneous epithelial cell disorder. HLP is the only
EBV-associated disease in which acyclovir, an antiviral drug
that inhibits the replication of EBV, induces clinical remis-
sion (2). This response and the detection of masses of viral
particles in the infected cells make these lesions unique in
EBV biology and indicate that the virus is actively replicating
(1, 2).
Replication is relatively unusual in EBV-infected cells.
Although the virus replicates in oropharyngeal epithelial
cells, the transforming infection of B lymphocytes, which is
the hallmark of EBV infection, is largely nonpermissive
(3-6). In the latently infected B-cell lines, the viral DNA is
maintained as an episome (7, 8). Permissive infection devel-
ops in a small subset of cells with the expression of multiple
replicative RNAs and the generation ofthe linear, virion form
of DNA. The structure of the EBV termini permits discrim-
ination between the linear and episomal DNA forms and
therefore between permissive and latent states (9, 10).
In EBV-infected cells, the most abundantly expressed viral
transcripts are the nonpolyadenylylated polymerase III tran-
scripts, EBER1 and EBER2 (EBV-encoded small nuclear
RNA), which are found in ribonucleoprotein particles (RNP)
(11, 12). Despite their abundance, the function ofthese RNAs
is unknown. The EBERs can partially substitute for the
similarly sized polymerase III virus-associated (VA) tran-
scripts encoded by adenovirus that function during viral
replication (13, 14). This complementation suggested that
perhaps, like the VA RNAs, the EBERs also function during
lytic replication. This observation was supported by studies
that revealed that the EBERs are more abundant in the
partially permissive virus-producer cell line B95-8 than in a
latently infected lymphoid line, IB4, established by infection
with B95-8 virus (15, 16). However, in contrast to the
cytoplasmic VA RNAs, which are expressed late after in-
fection, the EBERs are expressed early after infection and
detected predominantly in the nucleus (17, 18).
In this study, the state ofEBV infection in HLP was further
characterized through analysis of the terminal restriction-
enzyme fragments of EBV. Analysis of the EBV termini
revealed that HLP is an unusually permissive infection with
abundant ladder arrays representing virion DNA. EBV rep-
licative mRNAs and the latent membrane protein (LMP)
mRNA were expressed in the infected tissues; however, the
EBER RNAs could not be detected in most specimens.
EBER expression was detected in a few cells in in situ
hybridizations. These data indicate that the EBER RNAs,
which are abundantly expressed in latently infected cells, are
not expressed in permissively infected cells and are not
required for viral replication.
MATERIALS AND METHODS
Cell Cultures and Tissue Specimens. The lymphoblastoid
B-cell lines B95-8, AG876, Raji, Louckes, and CB4 were
grown at 370C in RPMI 1640 medium with 10% (vol/vol) fetal
calf serum and antibiotics. The B95-8 and AG876 cell lines
were treated with 40 ng of phorbol 12-myristate 13-acetate to
induce viral replication. The nasopharyngeal carcinoma
(NPC) cell line NPC-KT was maintained in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf
serum (19). The NPC tumor C15 is an undifferentiated,
nonkeratinizing NPC, which has been serially propagated in
nude mice (20).
Nucleic Acid Extraction and Blotting. Tissue specimens of
HLP and NPC were obtained at biopsy, frozen, pulverized in
a microdismembrator (Braun Instruments/Fisher Scientific),
and dissolved in 4 M guanidine thiocyanate (21, 22). Total
cellular RNA was obtained from the cell lines by resuspend-
ing the pelleted cells in 4 M guanidine thiocyanate (23). RNA
and DNA were separated by centrifugation through a cesium
chloride step gradient. The DNA fraction was dialyzed,
treated with proteinase K, and extracted with phenol and
chloroform prior to digestion with restriction enzymes and
electrophoresis through a 0.6% agarose gel. Polyadenyly-
lated mRNA was enriched by oligo(dT)-cellulose chromatog-
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raphy prior to electrophoresis through a 0.8% agarose/
formaldehyde gel or through a 2% NuSieve agarose gel (24).
Preparation of Radiolabeled Probes. Single-stranded RNA
probes were synthesized from the EBV fragments cloned into
the pGEM vector (Promega) by using either SP6 or T7 RNA
polymerase in a 50-Ail reaction mixture consisting of 40 mM
Tris HCI (pH 7.5), 6 mM MgCI2, 2 mM spermidine, 100 ,ug of
bovine serum albumin per ml, 10 mM dithiothreitol, 0.5 mM
unlabeled nucleotides, and 120 uCi of [32P]UTP. The EBV
fragments used to identify the terminal fragments were the
EcoRII portion ofBamHI NJhet, adjacent to the left terminal
repeats (TRs) and the Xho I 1.9-kilobase (kb) fragment rep-
resenting unique DNA adjacent to the right TRs (9, 25). RNA
probes were synthesized from the BamHI Z, H, and L
fragments to identify EBV replicative mRNAs, from the Xho
I 1.9-kb fragments to identify LMP mRNA, and from the
EcoRI J fragment to identify the EBER RNAs. The EBER1-
specific probe is a 1.45-kb Sau3A subfragment of EcoRI J
fragment (bases 5418-6794).
Hybridization Conditions in Situ. Frozen biopsies of HLP
were fixed in 4% paraformaldehyde/0.1% deoxycholate/
0.1% Triton X-100 in phosphate-buffered saline. The HLP
tissues were divided in pieces and hybridized at 50°C [in 50o
formamide/600 mM sodium chloride/1 mM EDTA/10 mM
dithiothreitol/10% SDS/110o PEG 8000/0.25 mg of Esche-
richia coli tRNA per mI/10 mM Tris-HCI, pH 7.5/0.02%
Ficoll/0.02% bovine serum albumin/0.02% polyvinylpyrroli-
done] to antisense and sense RNA probes representing LMP
and EBER RNAs. The probes were hydrolyzed in alkali to
-100-200 base pairs (bp). After hybridization the tissues
were treated with ribonuclease A (20 ,ug/ml) in 500 mM
NaCI/10 mM Tris, pH 8.0, at 37°C for 30 min. The tissue was
washed, dehydrated, fixed, and sectioned. Slides were
coated with Kodak NTB2 emulsion and exposed for 1-3
weeks.
RESULTS
The Structure of the EBV Termini in HLP. The terminal
restriction enzyme fragments of linear virion DNA are het-
erogeneous in size and vary by increments of 500 bp reflect-
ing differing numbers of copies of direct tandem repeats of
'=500 bp at each terminus (TR) (26, 27). Fused terminal
fragments are formed after infection through thejoining ofthe
ends of the linear DNA to form the intracellular, episomal
form of EBV (25, 27). The fused terminal fragments can be
distinguished from the terminal fragments of the linear ge-
nomes because they will hybridize to DNA probes of unique
DNA adjacent to the TR from both ends of the linear genome
(9). This type of analysis revealed a single band representing
the fused EBV termini in NPC, an EBV-associated epithelial
malignancy, as well as in monoclonal lymphomas (9, 22). The
detection of homogeneous, clonal EBV genomes indicated,
by extension, cellular clonality. Similar analyses of cell lines
cloned in vitro and EBV-infected lymphoproliferations in
vivo identified predominant clonal or oligoclonal fused ter-
minal fragments and faint ladder arrays representing linear
DNAs (10, 28).
In HLP tissue, EBV virions are detected. However, in
contrast to lytic infections with other herpesviruses, in HLP
the infected cells continue to proliferate and produce keratin
filaments, an observation that inspired the appellation
"hairy" leukoplakia. Total intracellular DNA was extracted
fron tissue biopsy specimens representing active HLP. Du-
plicate Southern blots prepared with DNA from five speci-
mens ofHLP were hybridized to probes representing unique
DNA from the left or right ends of the linear EBV genome,
adjacent to the TRs (Fig. 1). In contrast to the pattern of
terminal fragments detected in NPC, lymphomas, lym-
phoproliferations, and B-cell lines, in HLP abundant ladder
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FIG. 1. The structure of the EBV termini in HLP. Duplicate blots
prepared with DNA extracted from five specimens of HLP digested
with BamHI were hybridized to SP6-generated RNA probes repre-
senting the EcoRII portion ofBamHI NJhet, adjacent to the left TRs
(lanes L) and to the Xho I 1.9-kb fragment representing unique DNA
adjacent to the right TRs (lanes R) (6).
arrays representing the left (L) or right (R) termini were
detected without evidence of predominant fused fragments
representing episomal DNA. Although it is likely that the
multiple larger fragments are heterogeneous fused terminal
fragments, which would include replicative intermediates,
the lack of predominant fused fragments indicates that HLP
is not a reactivation ofEBV with clonal or oligoclonal cellular
proliferation and viral replication in some ofthe cells. Rather,
the unusual pattern of the termini in HLP indicates that HLP
is primarily a permissive EBV infection. Interestingly, the
periodicity of the EBV terminal fragments varies between
specimens. This suggests that perhaps the size of the TR is
distinct in these wild-type strains.
Analysis of EBV Transcription in HLP. All studies of EBV
expression during replication have analyzed mixed popula-
tions of cells where a large portion of the cells is latently
infected. Therefore, HLP provides a unique opportunity to
analyze expression of replicative functions. However, in
most cases, the total RNA obtained from a 2- to 3-mm HLP
biopsy specimen was sufficient for one or two Northern
blots. Therefore, the top portion of the blot was hybridized
to an EBV probe to identify specific EBV replicative RNAs,
and the bottom portion was hybridized to probes specific for
the EBERs. Transcription in HLP was compared with tran-
scription in latently and permissively infected lymphoid lines,
an EBV-infected epithelial cell line, and a latently infected
NPC passaged in nude mice (29, 30). The two strain variants
of EBV, A and B, which have considerable sequence diver-
gence in the Epstein-Barr nuclear antigen EBNA2 gene, were
also included (31). The EBER genes are 99% homologous
between the two strains; however, a point mutation results in
a restriction enzyme polymorphism that can distinguish A
and B types (32).
The late fiiRNAs that encode the glycoproteins gp350 and
gp220, the two major envelope proteins of EBV, are tran-
scribed from the BamHI L fragment (33, 34). A single-
stranded RNA probe transcribed rightward identified the 3.3-
and 2.8-kb mRNAs that encode the envelope proteins and a
late 1.8-kb mRNA also transcribed from these sequences in
two specimens ofHLP (Fig. 2A). These late mRNAs were not
detected in the RNA obtained from the latently infected
Mic'robiology: Gilligan et al.
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FIG. 2. Identification of EBV late and early transcription in HLP. (A) Northern blot prepared from a 2% NuSieve gel containing total RNA
extracted from two HLP biopsies (lanes Ho and Di) and 5 gg each of nonpolyadenylylated RNA from NPC-KT, a cell line formed by fusion
of an NPC with an established adenocarcinoma cell line (lane NKT) (30); from C15, an NPC passaged in nude mice (lane C15) (20); and nuclear
and cytoplasmic RNA from the Raji cell line (lanes Rn and Rc). The blot was cut in half to separate the high and low molecular weight RNAs.
The top half of the blot was hybridized to a single-stranded RNA probe homologous to leftward BamHI L fragment mRNAs encoding the viral
envelope glycoproteins gp350 and gp220 (3.3 and 2.8 kb). The bottom half was hybridized to an RNA probe that was tratiscribed leftward from
the EcoRI J fragment and is homologous to the EBER RNAs (0.17 kb). The 5.2- and 2.0-kb ribosomal RNAs are denoted by arrows on the right.
The approximate sizes of detected bands are indicated in kilobases. (B) A second Northern blot was prepared from a 1% agarose gel containing
total RNA extracted from one HLP specimen (lane La) and 5 ,g each of polyadenylylated RNA from phorbol 12-myristate 13-acetate
(PMA)-induced AG876 (lane AG), Raji (lane Ra), Louckes, an EBV-negative American Burkitt lymphoma (lane Lo), and PMA-induced B95-8
(lane B95). This blot was cut in half and the top half was hybridized to a single-stranded RNA probe homologous to rightward transcripts of
BamHI H fragment. The bottom half was hybridized to EcoRI J fragment.
NPC-KT and C15 NPC epithelial cells or cytoplasmic and
nuclear RNA from the Raji cell line. Hybridization of the
bottom panel to EcoRI J fragment identified the EBERs in
NPC-KT, C15, and Raji cells but did not detect EBER
expression in the HLP RNAs.
Several early replicative mRNAs are transcribed from the
BamHI H fragment of EBV (15, 35). The multiple RNAs,
transcribed from left to right in BamHI H fragment, are 3'
coterminal and encode a 17-kDa early replicative protein (36).
A Northern blot was prepared with total RNA extracted from
HLP and with RNA obtained from the EBV producer cell
lines B95-8 and AG876 (which represent the prototype A and
B strains), the latently infected Raji cell lines, and the
EBV-negative lymphoid line Louckes. Hybridization with a
leftward RNA probe transcribed from BamHI H fragment
identified the 2.4- and 1.6-kb mRNAs in B95-8 RNA and the
1.6-kb mRNA in AG876. Strong hybridization was detected
to the HLP RNA sample La. Hybridization of the bottom
panel to EcoRI J fragment detected the EBERs in AG876,
B95-8, and Raji cells but did not detect EBER expression in
the La RNA. These data confirmed that HLP specimens
contain replicative EBV transcripts in the absence of detect-
able EBER transcription.
The EBV replication activator protein ZEBRA is an im-
mediate-early function that can activate expression of repli-
cative antigens (37, 38). Hybridization with a single-stranded
RNA probe synthesized rightward in map orientation from
the BamHI Z fragment identified the 4.6-kb, 3.4-kb, and
1.2-kb early mRNAs transcribed from BamHI Z fragment in
the polyadenylylated RNA from B95-8 and the 1.2-kb mRNA
in AG876 RNA (39). A low level of transcription was also
detected in Raji RNA. Abundant hybridization was also
detected to RNA extracted from the HLP specimen La (Fig.
3A). Hybridization with the BamHI Z probe identified mul-
tiple discrete mRNAs in two additional specimens, Hu and
Ma (Fig. 3B). In RNA from B95-8, large mRNA forms are
also detected in long exposures of the autoradiogram, indi-
cating that transcription into BamHI Z is complex (Fig. 3B).
Hybridization of the bottom portion of the blot to the
EcoRI J fragment (Fig. 3A) or to a probe specific for EBER1
(Fig. 3B) detected expression of the EBERs in RNA fractions
from the B95-8, AG876, and Raji cell lines but did not detect
the EBERs in RNA from the HLP specimens. Long expo-
sures of the heavily loaded Ma channel detected trace levels
of hybridization to the EBER1 probe. These results indicated
that although EBV replicative RNAs were readily detected in
the RNA preparation from HLP specimens, the EBERs were
not detected or were expressed at trace levels.
The EBV LMP is expressed in all latently infected lym-
phoid cells; however, expression of LMP or a related trun-
cated protein transcribed from the same sequences increases
after induction of replication (40-42). Expression ofLMP can
transform rat fibroblasts in vitro and induces in transgenic
mice epithelial proliferation and hyperkeratin production (43,
44). Hybridization of an RNA probe homologous to LMP
detected the 2.8-kb LMP mRNA in B95-8 and 3.7-kb and
2.8-kb mRNAs in HLP RNA (Fig. 3C). A 3.7-kb mRNA
homologous to LMP also has been detected in NPC, an
epithelial malignancy associated with EBV (9, 45). Transcrip-
tion of the 3.7-kb LMP mRNA in both HLP and NPC may
indicate that this form of LMP mRNA is transcribed more
frequently in epithelial cells.
The EBER RNAs are generally resistant to degradation,
perhaps because they are found in RNP particles and can
readily be detected in most RNA preparations even when
mRNAs are not detectable. The absence of detectable
EBERs in HLP RNA preparations where replicative tran-
scripts were detected indicates that the EBERs are not
transcribed in permissive infection and are not required for
EBV replication. Previous studies had revealed that EBER
abundance did not detectably change when a predominantly
latent cell line was induced to a high percentage of lytically
infected cells (46). However, these studies could not deter-
mine whether EBERs, which were present in the latently
infected cells prior to induction, also functioned in the
permissively infected cells.
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FIG. 3. Identification of EBV immediate-early and latent transcription in HLP. (A) An identical Northern blot of Fig. 2B was prepared and
cut in half to separate high and low molecular weight RNAs. The top portion of the blot was hybridized to a single-stranded RNA probe
homologous to leftward transcripts of BamHI Z fragment. The bottom portion was hybridized to an EcoRI J fragment RNA probe. The
approximate sizes of the detected RNAs are indicated in kilobases. (B) A Northern blot was prepared with total RNA from two HLP specimens
(lanes Ma and Hu), and 10 ,ug of B95-8 (lane B95). The blot was cut in half, the top was hybridized to the BamHI Z fragment probe, and the
bottom was hybridized to a probe homologous to EBERL. The lane on the right contains 5 ,Ag of polyadenylylated B95-8 RNA hybridized to
the BamHI Z probe, identifying additional transcripts after lengthy exposure to x-ray film. (C) A duplicate Northern blot of Fig. 3B containing
HLP (Ma) and B95-8 (B95) total cellular RNA was hybridized to an Xho I 1.9-kb probe homologous to LMP (Upper) or to the EBER1 probe
(Lower).
Analysis of EBV Transcription by in Situ Hybridization.
Activation ofEBV replication is believed to occur as oropha-
ryngeal epithelial cells differentiate (4). It is possible that the
EBERs and perhaps other functions that are expressed in
latently infected cells may be localized to the more undiffer-
entiated cells and not be detected in RNA prepared from the
whole tissue homogenate. Therefore, specimens of HLP
were analyzed by in situ hybridization with 35S-labeled
single-stranded RNA probes specific for EBER1 and the
EBV LMP in antisense and sense orientation. Hybridization
with the LMP antisense probe detected expression in all
layers of the infected tissue, with particularly strong hybrid-
ization in the differentiated squamous cell layer (Fig. 4A).
Hybridization was not detected with the LMP sense probe
(Fig. 4B), indicating that the hybridization was specific for





ization with the LMP antisense probe to EBV-negative
normal glandular tissue from the nasopharynx was also
negative (Fig. 4C).
Hybridization with the EBER1 antisense probe did not
detect EBER expression in the majority of cells in the
superficial or basal layers of the HLP tissue (Fig. 4D). In
some specimens, grains were detected on an extremely rare
cell within the basal layer, denoted with an arrow. Such cells
perhaps represent an occasional cell that remains latently
infected and account for the trace levels of hybridization
detected on some Northern blots. In contrast, in NPC tissue,
which contains clonal EBV episomal DNA and is predomi-
nantly latently infected, EBER1 is abundantly transcribed
and readily detected by in situ hybridization (Fig. 4E).
Hybridization was not detected with EBER sense probe in
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FIG. 4. Identification of LMP and EBER RNA by in situ hybridization. (A) An SP6-generated 3"S-labeled antisense RNA probe synthesized
from an Xho I 1.9-kb fragment homologous to LMP RNA was hybridized to a portion of a shave biopsy of HLP. (B) A 35S-labeled LMP sense
RNA probe was hybridized to a second portion of the HLP biopsy. (C) Hybridization of the LMP antisense probe to normal nasopharyngeal
glandular tissue. (D) Hybridization of the 35S-labeled EBERl-specific antisense RNA probe to an HLP specimen. (E) Hybridization of the
3"S-labeled EBER antisense probe to C15 NPC tissue. (F) Hybridization of a 3"S-labeled EBER1 sense probe to C15 NPC tissue. (x 140.)
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consistently detected in the HLP tissue sections, EBER
expression was not detected in 10 HLP specimens tested by
in situ hybridization. The LMP mRNA is present in lymphoid
cell lines at =20 copies per cell, whereas in some cell lines,
the EBER RNAs are detected at 107 copies per cell (17). The
ability of the in situ hybridizations to detect the low-
abundance LMP mRNA suggests that the EBERs are not
expressed at low levels in most cells in the HLP tissue.
DISCUSSION
These data, which reveal the absence of EBER expression in
most of the EBV-infected cells in HLP representing permis-
sive infections, and previous studies, which detected nuclear
expression of the EBERs early after transformation, suggest
that the EBERs function during latent infection where they
may participate in RNA processing, stabilization, or trans-
port (17, 18). Structural and sequence analysis of the EBER
genes has revealed a seven-nucleotide sequence homologous
to the region of the cellular U6 small nuclear RNA, which is
involved in base-pairing with the U4 RNA in the RNP
spliceosome complex (47). This region of EBER2 is also
single-stranded in RNP particles, suggesting that EBER2
may hybridize with another RNA and potentially could
function during the intricate RNA splicing that is character-
istic of the latent mRNAs of EBV (48). Another key element
in the regulation of EBV expression during latent infection is
the selective stabilization and transport of transcripts (16).
The EBERs may participate in this process. This explanation
would be consistent with the predominant nuclear localiza-
tion with some detection in the cytoplasm.
In contrast to the lack of EBER expression in permissive
infection, LMP expression is maintained in the permissively
infected cells. Interestingly, HLP is characterized by abun-
dant keratin production and continued proliferation of the
epithelium, a phenotype exhibited by transgenic mice ex-
pressing LMP (44). The continued expression ofLMP in HLP
may provoke these histopathologic characteristics.
The lack of a permissive cell system and the resulting
inability to generate specific mutants have impeded the
identification of the specific biologic functions of EBV genes.
Therefore, a more indirect approach to ascertain potential
functions has been required. In most of the HLP specimens,
multiple strains of EBV of both the A and B types can be
identified, with some specimens containing four to six dis-
tinct strains of EBV (N.R.-T., unpublished observation). The
complete lack of EBER expression in HLP during the rep-
lication of multiple strains of EBV indicates that the EBERs
are not transcribed from any of the coinfecting viral genomes
in the permissively infected cells.
These data indicate that the EBERs are not required for
replication and therefore must participate in maintaining
latency. Moreover, this study reveals that EBER transcrip-
tion can be considered a marker of latent EBV infection,
whereas LMP is expressed in both latently and permissively
infected cells. The relative stability of the EBERs and their
considerable abundance allow for consistent detection by in
situ hybridization which may be useful as a diagnostic tool.
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